Search Results Search Sort by RelevanceMost Recent Case and Commentary Apr 2019 How Should Physicians Help Patients Understand Unknowns of Nanoparticle-Based Medicines? Nancy M. P. King, JD and Christine E. Bishop, MD, MA When an unproven intervention is a nanodrug, a physician’s role is especially difficult due to possibilities of unprecedented harms. AMA J Ethics. 2019;21(4):E324-331. doi: 10.1001/amajethics.2019.324. Case and Commentary May 2019 How Should Physicians Respond to Requests for LVAD Removal? Larry A. Allen, MD, MHS Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward. AMA J Ethics. 2019;21(5):E394-400. doi: 10.1001/amajethics.2019.394. Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Nov 2019 Should a Caregiver’s QoL Be Considered in Decisions About Whether a Patient Has an Experimental Double-Hand Transplant? Miguel I. Dorante, MD, MBE, Elaine Devine, MSW, LICSW, and Simon G. Talbot, MD Success depends on strong support, rehabilitation, adherence, and social integration. AMA J Ethics. 2019;21(11):E943-952. doi: 10.1001/amajethics.2019.943. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Case and Commentary Jul 2019 Should Aggregate Patient Preference Data Be Used to Make Decisions on Behalf of Unrepresented Patients? Nathaniel Sharadin, PhD, MA Ethical and practical problems with preference modeling can undermine how reliably predictors can be used in high-stakes decisions. AMA J Ethics. 2019;21(7):E566-574. doi: 10.1001/amajethics.2019.566. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Case and Commentary Apr 2020 What Should an Anesthesiologist and Surgeon Do When They Disagree About Terms of Perioperative DNR Suspension? Alexander E. Loeb, MD, Shawn Y. Jia, MD, and Casey J. Humbyrd, MD Using alternative anesthesia techniques requires collaborative decision making that expresses a patient’s best interest. AMA J Ethics. 2020;22(4):E283-290. doi: 10.1001/amajethics.2020.283. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Next page Next › Last page Last »
Case and Commentary Apr 2019 How Should Physicians Help Patients Understand Unknowns of Nanoparticle-Based Medicines? Nancy M. P. King, JD and Christine E. Bishop, MD, MA When an unproven intervention is a nanodrug, a physician’s role is especially difficult due to possibilities of unprecedented harms. AMA J Ethics. 2019;21(4):E324-331. doi: 10.1001/amajethics.2019.324.
Case and Commentary May 2019 How Should Physicians Respond to Requests for LVAD Removal? Larry A. Allen, MD, MHS Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward. AMA J Ethics. 2019;21(5):E394-400. doi: 10.1001/amajethics.2019.394.
Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Nov 2019 Should a Caregiver’s QoL Be Considered in Decisions About Whether a Patient Has an Experimental Double-Hand Transplant? Miguel I. Dorante, MD, MBE, Elaine Devine, MSW, LICSW, and Simon G. Talbot, MD Success depends on strong support, rehabilitation, adherence, and social integration. AMA J Ethics. 2019;21(11):E943-952. doi: 10.1001/amajethics.2019.943.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
Case and Commentary Jul 2019 Should Aggregate Patient Preference Data Be Used to Make Decisions on Behalf of Unrepresented Patients? Nathaniel Sharadin, PhD, MA Ethical and practical problems with preference modeling can undermine how reliably predictors can be used in high-stakes decisions. AMA J Ethics. 2019;21(7):E566-574. doi: 10.1001/amajethics.2019.566.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
Case and Commentary Apr 2020 What Should an Anesthesiologist and Surgeon Do When They Disagree About Terms of Perioperative DNR Suspension? Alexander E. Loeb, MD, Shawn Y. Jia, MD, and Casey J. Humbyrd, MD Using alternative anesthesia techniques requires collaborative decision making that expresses a patient’s best interest. AMA J Ethics. 2020;22(4):E283-290. doi: 10.1001/amajethics.2020.283.